AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37659430 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent high risk of cardiovascular disease
Number of subjects: 370
Study 37659430 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical carotid atherosclerosis
Number of subjects: 370
Study 37659430 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance of cardiovascular health during midlife
Number of subjects: 370
Study 37659435 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 100
Study 37659435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 37659505 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CGD
Number of subjects: 79
Study 37659505 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CGD-IBD
Number of subjects: 79
Study 37659505 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 79
Study 37659585 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter occlusion
Number of subjects: 64580
Study 37659585 — intervention group
Group type: COMPARATOR
Intervention: Surgical ligation
Number of subjects: 64580
Study 37659585 — intervention group
Group type: COMPARATOR
Intervention: Overall procedural closure
Number of subjects: 64580
Study 37659585 — intervention group
Group type: EXPERIMENTAL
Intervention: Median age at surgical ligation
Number of subjects: 64580
Study 37659585 — intervention group
Group type: EXPERIMENTAL
Intervention: Median age at transcatheter occlusion
Number of subjects: 64580
Study 37659594 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth UI application (MyHealtheBladder)
Number of subjects: 286
Study 37659594 — intervention group
Group type: COMPARATOR
Intervention: VA Video Connect (VVC) session delivered by trained UI providers
Number of subjects: 286
Study 37659673 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg
Number of subjects: 313
Study 37659673 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 400 mg
Number of subjects: 313
Study 37659673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 37659673 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg (nonresponders at week 12)
Number of subjects: 313
Study 37659673 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 400 mg (nonresponders at week 12)
Number of subjects: 313
Study 37659841 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (rapid access to ART, naltrexone for opioid use disorder, strengths-based case management)
Number of subjects: 225
Study 37659841 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 225
Study 37659907 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Number of subjects: 80
Study 37660032 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Up and Go dual-task test (TUGdt) with verbal tasks (TUGdt-NA and TUGdt-MB)
Number of subjects: 186
Study 37660032 — intervention group
Group type: EXPERIMENTAL
Intervention: TUGdt-NA words/time
Number of subjects: 186
Study 37660032 — intervention group
Group type: EXPERIMENTAL
Intervention: TUGdt-MB words/time
Number of subjects: 186
Study 37660032 — intervention group
Group type: EXPERIMENTAL
Intervention: TUGdt parameters (time scores and TUGdt cost)
Number of subjects: 186
Study 37660032 — intervention group
Group type: EXPERIMENTAL
Intervention: Step length during TUGdt
Number of subjects: 186
Study 37660038 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath gas analysis using multi-capillary column ion mobility spectrometry (MCC-IMS)
Number of subjects: 380
Study 37660042 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 120
Study 37660042 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 120
Study 37660042 — intervention group
Group type: COMPARATOR
Intervention: Control (Medication and Traditional Physiotherapy)
Number of subjects: 120
Study 37660052 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg dexamethasone
Number of subjects: 300
Study 37660052 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 300
Study 37660376 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin clot properties
Number of subjects: 0
Study 37660438 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 1509
Study 37660438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1509
Study 37660534 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-transcript model (ADGRG3, ATG2A, GNLY) from POD 7
Number of subjects: 52
Study 37660534 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-transcript model (IGHM, CD5, GNLY) from M3
Number of subjects: 52
Study 37660534 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 3-transcript models with eGFR at POD 7
Number of subjects: 52
Study 37660534 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 3-transcript models with eGFR at M3
Number of subjects: 52
Study 37660535 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1-based immunotherapy with tumor PD-L1 determined in lymph node metastases
Number of subjects: 448
Study 37660535 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1-based immunotherapy with tumor PD-L1 determined in primary tumors
Number of subjects: 448
Study 37660535 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1-based immunotherapy with tumor PD-L1 determined in skin/subcutaneous metastases
Number of subjects: 448
Study 37660633 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) stove intervention; n = 1,590
Number of subjects: 3195
Study 37660633 — intervention group
Group type: COMPARATOR
Intervention: Control group using biomass fuels; n = 1,605
Number of subjects: 3195
Study 37660704 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dupilumab (300 mg)
Number of subjects: 227
Study 37660704 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Weekly dupilumab
Number of subjects: 227
Study 37660704 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab every 2 weeks (300 mg)
Number of subjects: 227
Study 37660704 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Every 2 weeks dupilumab
Number of subjects: 227
Study 37660711 — intervention group
Group type: EXPERIMENTAL
Intervention: V160 three-dose regimen (V160 at day 1, month 2, and month 6)
Number of subjects: 2220
Study 37660711 — intervention group
Group type: EXPERIMENTAL
Intervention: V160 two-dose regimen (V160 on day 1, placebo at month 2, and V160 at month 6)
Number of subjects: 2220
Study 37660711 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution at day 1, month 2, and month 6)
Number of subjects: 2220
Study 37660711 — intervention group
Group type: EXPERIMENTAL
Intervention: V160 three-dose regimen
Number of subjects: 2220
Study 37660711 — intervention group
Group type: EXPERIMENTAL
Intervention: V160 two-dose regimen
Number of subjects: 2220
Study 37660711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2220
Study 37660715 — intervention group
Group type: EXPERIMENTAL
Intervention: Idrevloride in hypertonic saline
Number of subjects: 123
Study 37660715 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline alone
Number of subjects: 123
Study 37660715 — intervention group
Group type: EXPERIMENTAL
Intervention: Idrevloride alone
Number of subjects: 123
Study 37660715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 37660952 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Self-Administered 24-h recalls (ASA24s)
Number of subjects: 1082
Study 37660952 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Frequency Questionnaires (FFQs)
Number of subjects: 1082
Study 37660952 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day Food Records (4DFRs)
Number of subjects: 1082
Study 37660952 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated use of 6 ASA24s, 2 FFQs, and 2 4DFRs
Number of subjects: 1082
Study 37661005 — intervention group
Group type: EXPERIMENTAL
Intervention: Know Your Risk (KYR) intervention
Number of subjects: 1000
Study 37661005 — intervention group
Group type: COMPARATOR
Intervention: Conventional genetic counseling
Number of subjects: 1000
Study 37661107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion of glucose (22.5 g, 1 kcal/min) and oleic acid (10 g, 1 kcal/min) for 90 min
Number of subjects: 25
Study 37661107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion with benzocaine
Number of subjects: 25
Study 37661107 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal nutrient infusion
Number of subjects: 25
Study 37661107 — intervention group
Group type: COMPARATOR
Intervention: Nutrient-induced hunger and satiety sensations
Number of subjects: 25
Study 37661237 — intervention group
Group type: EXPERIMENTAL
Intervention: Mattress (MAT)
Number of subjects: 20
Study 37661237 — intervention group
Group type: COMPARATOR
Intervention: Rigid surface (CON)
Number of subjects: 20
Study 37661554 — intervention group
Group type: EXPERIMENTAL
Intervention: fSAD-dominant (FD)
Number of subjects: 1495
Study 37661554 — intervention group
Group type: EXPERIMENTAL
Intervention: emphysema-dominant (ED)
Number of subjects: 1495
Study 37661554 — intervention group
Group type: EXPERIMENTAL
Intervention: fSAD-transition (FT)
Number of subjects: 1495
Study 37661670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheostomy opening
Number of subjects: 26
Study 37661670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheostomy closure
Number of subjects: 26
Study 37661670 — intervention group
Group type: EXPERIMENTAL
Intervention: Accidental decannulation (early complication)
Number of subjects: 26
Study 37661670 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration pneumonia (late complication)
Number of subjects: 26
Study 37661670 — intervention group
Group type: EXPERIMENTAL
Intervention: Subglottic stenosis (late complication)
Number of subjects: 26
Study 37661670 — intervention group
Group type: EXPERIMENTAL
Intervention: Accidental decannulation (late complication)
Number of subjects: 26
Study 37661670 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprastomal collapse (late complication)
Number of subjects: 26
Study 37661670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheocutaneous fistula (late complication)
Number of subjects: 26
Study 37661670 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulation tissue (late complication)
Number of subjects: 26
Study 37661830 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic scoring of home polygraphy (PG)
Number of subjects: 54
Study 37661830 — intervention group
Group type: COMPARATOR
Intervention: Manual scoring of home polygraphy (PG)
Number of subjects: 54
Study 37662485 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37662520 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsaclisib 20 mg once daily for 8 weeks then 2.5 mg QD (daily dosing group [DG])
Number of subjects: 126
Study 37662520 — intervention group
Group type: COMPARATOR
Intervention: Parsaclisib 20 mg once daily for 8 weeks then 20 mg once weekly (weekly dosing group [WG])
Number of subjects: 126
Study 37662589 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioengineered human acellular vessels (HAVs)
Number of subjects: 355
Study 37662589 — intervention group
Group type: COMPARATOR
Intervention: Commercial expanded polytetrafluoroethylene (ePTFE) grafts
Number of subjects: 355
Study 37662595 — intervention group
Group type: EXPERIMENTAL
Intervention: sucrosomial Vitamin D3 (200,000 IU weekly)
Number of subjects: 25
Study 37662595 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 treatment (not specified)
Number of subjects: 25
Study 37662597 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ)
Number of subjects: 180
Study 37662597 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with beetroot juice (BJ + MeD)
Number of subjects: 180
Study 37662597 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MeD)
Number of subjects: 180
Study 37662597 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 180
Study 37663034 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 218
Study 37663146 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 20
Study 37663146 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 20
Study 37663201 — intervention group
Group type: EXPERIMENTAL
Intervention: METS-VF
Number of subjects: 185
Study 37663201 — intervention group
Group type: EXPERIMENTAL
Intervention: WC
Number of subjects: 185
Study 37663201 — intervention group
Group type: COMPARATOR
Intervention: ABSI
Number of subjects: 185
Study 37663201 — intervention group
Group type: COMPARATOR
Intervention: VAI
Number of subjects: 185
Study 37663201 — intervention group
Group type: COMPARATOR
Intervention: WHR
Number of subjects: 185
Study 37663201 — intervention group
Group type: COMPARATOR
Intervention: BMI
Number of subjects: 185
Study 37663201 — intervention group
Group type: COMPARATOR
Intervention: BRI
Number of subjects: 185
Study 37663201 — intervention group
Group type: COMPARATOR
Intervention: LAP
Number of subjects: 185
Study 37663359 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous telerehabilitation program with a neuropsychologist, nutritionist, and physiotherapist for 6 weeks
Number of subjects: 26
Study 37663359 — intervention group
Group type: COMPARATOR
Intervention: Informative booklet and weekly phone calls for 6 weeks
Number of subjects: 26
Study 37663593 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment (EA) using sacral acupoints
Number of subjects: 360
Study 37663593 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment (EA) using abdominal acupoints
Number of subjects: 360
Study 37663593 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment (EA) using alternating acupoints
Number of subjects: 360
Study 37663593 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment (EA)
Number of subjects: 360
Study 37663954 — intervention group
Group type: EXPERIMENTAL
Intervention: FiApp smartphone-based application for self-monitoring fluid intake
Number of subjects: 25
Study 37664025 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (20 mg/day) plus Pembrolizumab (200 mg every 3 weeks)
Number of subjects: 0
Study 37664025 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (50 mg/day, 4 weeks on, 2 weeks off)
Number of subjects: 0
Study 37664409 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-omics model with modified synthetic down sampling and up sampling
Number of subjects: 2457
Study 37664409 — intervention group
Group type: COMPARATOR
Intervention: Agatston scoring
Number of subjects: 2457
Study 37664485 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 25mg
Number of subjects: 1337
Study 37664485 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 12.5mg
Number of subjects: 1337
Study 37664485 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1337
Study 37664560 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pfCa monitoring (aiming pfCa level of 0.25-0.35 mmol/L)
Number of subjects: 50
Study 37664560 — intervention group
Group type: COMPARATOR
Intervention: No pfCa monitoring (constant citrate infusion at 4 mmol/L)
Number of subjects: 50
Study 37664999 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month training programme designed to improve endurance
Number of subjects: 5
Study 37665178 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor 40 mg/m2 with mitoxantrone, etoposide, and cytarabine (MEC)
Number of subjects: 23
Study 37665397 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.15 µg kg continuous intravenous infusion)
Number of subjects: 24
Study 37665397 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (control group)
Number of subjects: 24
Study 37665397 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 24
Study 37665472 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of the Diabetes Eating Problem Survey-Revised (DEPS-R)
Number of subjects: 100
Study 37665472 — intervention group
Group type: EXPERIMENTAL
Intervention: EDE-Q
Number of subjects: 100
Study 37665497 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free oxybuprocaine hydrochloride 0.4% unit-dose eye drops, five times daily postoperatively until complete epithelial healing
Number of subjects: 72
Study 37665497 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate 0.2%
Number of subjects: 72
Study 37665497 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 72
Study 37665565 — intervention group
Group type: EXPERIMENTAL
Intervention: Governmental non-pharmaceutical interventions (NPI's)
Number of subjects: 19
Study 37665565 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 Stringency Index
Number of subjects: 19
Study 37665622 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement System for PrEP Uptake and Adherence (MES-PrEP) and motivational text messaging (MTM)
Number of subjects: 120
Study 37665622 — intervention group
Group type: COMPARATOR
Intervention: Standard PrEP counseling
Number of subjects: 120
Study 37665777 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 566
Study 37665777 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus Pegylated Liposomal Doxorubicin (PLD)
Number of subjects: 566
Study 37665777 — intervention group
Group type: COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Number of subjects: 566
Study 37665832 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) counselling
Number of subjects: 14
Study 37665877 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized pleasure-oriented exercise sessions with enhancements for promoting pleasure (individualization based on preference and tolerance, self-regulation of intensity, repeated assessments of core affect)
Number of subjects: 46
Study 37665877 — intervention group
Group type: COMPARATOR
Intervention: General American College of Sports Medicine exercise prescription
Number of subjects: 46
Study 37665877 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized pleasure-oriented exercise sessions
Number of subjects: 46
Study 37666262 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education interventions (nutrition information during flag ceremonies, classroom lessons, school club meetings, peer group mentoring, BMI measurement and counselling, and parent-teacher meetings) for 4 months.
Number of subjects: 536
Study 37666262 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard academic curriculum on health and nutrition).
Number of subjects: 536
Study 37666264 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib combined with nivolumab and FOLFOX chemotherapy
Number of subjects: 39
Study 37666383 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy
Number of subjects: 229
Study 37666383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 37666539 — intervention group
Group type: EXPERIMENTAL
Intervention: Olvimulogene nanivacirepvec (Olvi-Vec) followed by platinum-doublet chemotherapy and bevacizumab
Number of subjects: 186
Study 37666539 — intervention group
Group type: COMPARATOR
Intervention: Platinum-doublet chemotherapy and bevacizumab
Number of subjects: 186
Study 37666548 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Number of subjects: 968
Study 37666548 — intervention group
Group type: COMPARATOR
Intervention: Tubal ligation
Number of subjects: 968
Study 37666557 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed learning with an integrated learning video
Number of subjects: 224
Study 37666557 — intervention group
Group type: COMPARATOR
Intervention: Traditional teacher-led workshop
Number of subjects: 224
Study 37666656 — intervention group
Group type: EXPERIMENTAL
Intervention: eCura scoring system
Number of subjects: 314
Study 37666656 — intervention group
Group type: EXPERIMENTAL
Intervention: W-eCura scoring system
Number of subjects: 314
Study 37666656 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive vertical margin, lymphatic invasion, and younger age
Number of subjects: 314
Study 37666695 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Invaplex (Invaplex)
Number of subjects: 0
Study 37666709 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized protocol for diagnosing NTM-PD in pwCF
Number of subjects: 0
Study 37666816 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized postprandial glucose-targeting diet
Number of subjects: 200
Study 37666816 — intervention group
Group type: COMPARATOR
Intervention: Standard of care Mediterranean diet
Number of subjects: 200
Study 37667204 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose primaquine
Number of subjects: 2336
Study 37667204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2336
Study 37667207 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPVB) for postoperative analgesia after video-assisted thoracoscopic surgery (VATS)
Number of subjects: 0
Study 37667207 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37667213 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF + Collagen Membrane (CM)
Number of subjects: 30
Study 37667213 — intervention group
Group type: COMPARATOR
Intervention: Open Flap Debridement (OFD)
Number of subjects: 30
Study 37667213 — intervention group
Group type: COMPARATOR
Intervention: L-PRF
Number of subjects: 30
Study 37667379 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced respiratory mechanics assessments (including esophageal pressure measurements and complete airway closure detection)
Number of subjects: 149
Study 37667379 — intervention group
Group type: COMPARATOR
Intervention: Basic assessments
Number of subjects: 149
Study 37667379 — intervention group
Group type: EXPERIMENTAL
Intervention: End-expiratory esophageal pressure measurements
Number of subjects: 149
Study 37667407 — intervention group
Group type: EXPERIMENTAL
Intervention: MyRelief educational platform
Number of subjects: 0
Study 37667507 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA fully-mismatched sibling-derived CD7 CAR-T therapy
Number of subjects: 1